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genetics, which has laid the foundation for our current
understanding of the etiological and pathogenic mecha-
nisms underlying AD as well as for the development
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Department of Neurology of novel approaches for treatment and prevention. As
Massachusetts General Hospital therapeutic strategies become more effective and our
114 16th Street grasp of AD genetics is strengthened, reliable and com-
Charlestown, Massachusetts 02129 prehensive genetic risk profiling will eventually enable
systematic early-prediction/early-prevention procedures.
In this minireview, we will present a brief history of AD
genetics and discuss its current and future status, focus-
Alzheimer’s disease (AD) is a genetically complex dis- ing on recent findings suggesting the existence of novel
order that accounts for the majority of dementia in and potentially important AD genes on chromosomes
the elderly population. Over 100 rare, highly penetrant 12, 10, and 9.
mutations have been described in three genes (APP, Genetics of AD: The Early Days
PSEN1, PSEN2) for early-onset familial AD. In the more Initial attempts to understand the role of genetics in AD
common late-onset form, a polymorphism in the apoli- in the early 1980s focused on rare multigenerational
poprotein E gene has been associated with increased families with early-onset (60), autosomal-dominant,
susceptibility. However, recent studies suggest that fully penetrant forms of the disease (EOFAD) using con-
these four genes account for less than 30% of the ventional linkage analysis (i.e., measuring cosegregation
genetic variance for AD and that more genetic factors of a genetic marker with disease phenotype) and subse-
remain to be identified. In this review, we present a quent positional cloning. Although the initial findings
brief history of AD genetics and preview some of the showing significant linkage of EOFAD to chromosome
next frontiers in Alzheimer gene discovery primarily 21 in 1987 were later found to be false positive findings
focusing on chromosomes 12, 10, and 9. (the same families were actually linked to another AD
locus on chromosome 14, see below), the implied region
Introduction harbored a compelling candidate gene for AD mutations:
Alzheimer’s disease (AD) is the most common form of the gene encoding the amyloid precursor protein (APP).
age-related dementia and one of the most serious health In 1990, the first APP mutation was discovered in a
problems in the U.S. AD is a progressive and insidious pedigree with Dutch type hereditary cerebral hemor-
neurodegenerative disorder of the central nervous sys- rhage with amyloidosis shortly followed by a missense
tem characterized by global deficits in cognition ranging mutation occurring in the same APP exon (exon 17) in
from loss of memory to impaired judgment and reason- patients with EOFAD (reviewed in Hardy, 1997; Price et
ing. Autopsy of AD patients’ brains reveals abundant al., 1998; Tanzi, 1999). Since then, 11 different pathoge-
amounts of neurofibrillary tangles and -amyloid in the netic mutations have been identified in APP, all of which
form of senile plaques and blood vessel deposits, both are missense mutations lying within or close to the do-
prerequisites for a confirmed diagnosis of AD (Price et main encoding the A peptide, the major component of
al., 1998). While the complete etiological picture of AD
-amyloid in AD (for an overview of all EOFAD mutations,
remains unresolved, the inheritance of predisposing ge-
see the AD Mutation Database at http://molgen-www.
netic factors appears to play a major role. After age,
uia.ac.be/ADMutations). Although the APP mutations
family history is the second greatest risk factor for AD.
account for less than 0.1% of all AD cases (Tanzi, 1999),There is also an emerging consensus that AD is a com-
they carry virtually complete penetrance leading to ADplex and genetically heterogeneous disorder that is best
between the fourth and seventh decades of life.explained by an age-dependent dichotomous model
Only a year after the first EOFAD mutation was found(Tanzi, 1999). AD is considered to be complex because
in APP, a second EOFAD locus was linked to chromo-there is no single (or simple) mode of inheritance that
some 14, and the gene was later identified and namedaccounts for its heritability; heterogeneous because mu-
presenilin 1 (PSEN1; reviewed in Hardy 1997; Price ettations and polymorphisms in multiple genes are in-
al., 1998; St George Hyslop, 2000; Tanzi, 1999). PSEN1volved together with nongenetic factors; dichotomous
encodes a highly conserved polytopic membrane pro-because early-onset familial AD (EOFAD) mutations are
tein that is required for -secretase activity necessaryrare, highly penetrant, and transmitted in an autosomal-
to liberate A from APP (Haass and De Strooper, 1999).dominant fashion, while increased risk for late-onset AD
EOFAD mutations in this gene as well as those in APPis conferred by common polymorphisms with relatively
and PSEN2 lead to an increase of secreted A42, thelow penetrance (but high prevalence). Adding to the
primary component of -amyloid plaques in the braincomplexity and heterogeneity of AD genetics are cur-
(reviewed in Price et al., 1998; Haass and De Strooper,rently ill-defined and difficult-to-model gene-to-gene
1999; Figure 1). Over the last 5 years, it has becomeand gene-to-environment interactions.
clear that the majority of EOFAD mutations identified toDespite these complexities, tremendous progress has
date reside in PSEN1. Six other EOFAD mutations occurbeen made over the past two decades in deciphering AD
in a gene encoding a second member of the presenilin
family called presenilin 2 (PSEN2) on chromosome 1.1Correspondence: tanzi@helix.mgh.harvard.edu
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ing the age of onset in a dose-dependent manner
(Blacker et al, 1997; Meyer et al., 1998). Some have
estimated that APOE-4 accounts for 50% of the “pre-
dicted total genetic effect” in AD based simply on the
prevalence of this allele in the patient population (versus
the control population where it is closer to 25%). How-
ever, a recent and more systematic study on over 700
AD cases from 75 families estimates the actual contribu-
tion of this polymorphism to onset of AD to be only
7%–9% (Daw et al., 2000). The pathophysiological con-
sequences of APOE-4 in AD include the enhanced ac-
cumulation of A in the brains of carriers as well as in
transgenic mice expressing the human 4 allele and
mutant APP (Poirier, 2000; St. George Hyslop, 2000;
Figure 1). Apolipoprotein E normally plays a role in cho-
lesterol transport and lipid metabolism. High plasma
cholesterol, in turn, has been firmly correlated with in-
creased -amyloid deposition in the brain. Interestingly,
Figure 1. Possible Pathogenetic Routes of A Production, Clear- cholesterol has also been shown to both increase A
ance, and Degradation
production and to stabilize the peptide in the brains of
Early-onset AD genes APP, PSEN1, and PSEN2 along with BACE
transgenic AD mice (Poirier, 2000). Thus, it is possible(-secretase) are involved in the production of A. The late-onset
that APOE-4 confers risk for AD via a mechanism thatAD gene APOE and the putative AD gene -1-antichymotrypsin
is shared in common with its effect on cardiovascular(ACT) have been proposed to play roles in the aggregation and
fibrillogenesis of A. APOE and putative AD genes LRP and A2M disease by increasing a carrier’s risk for hypercholester-
may play roles in the clearance of A as follows. Once 2M-A or olemia, as this would also elevate accumulation of A.
apoE-A complexes are internalized by LRP, they may be targeted The Search for Novel AD Genes
for endosomal recycling, lysosomal degradation, or undergo tran-
Over the last decade, more than three dozen associa-cytosis across the blood-brain barrier to the plasma. Membrane
tions have been reported between AD and candidateAPP containing an alternatively spliced Kunitz protease inhibitor
genes on nearly every chromosome in the genome.(KPI) domain may also undergo internalization by LRP and generate
A (dotted arrows) via the endocytic pathway. (Note: APP has also However, with the exception of APOE, none of these
been shown to undergo LRP-independent endocytosis.) Extracellu- findings has been consistently replicated (Tanzi, 1999;
lar degradation of A can occur via binding of the peptide to 2M Bertram and Tanzi, 2001). A recent study modeling AD
followed by degradation by an active protease (e.g., trypsin) bound as a quantitative trait locus (i.e., using a continuous
to the bait region of 2M. Alternatively, A may be degraded by
[age of onset] rather than a binary [affected/unaffected]“free” proteases, such as the insulin-degrading enzyme (IDE) or
phenotype definition) reported evidence for the exis-neprilysin (MME). Asterisk (*) denotes established AD genes.
tence of four to seven additional AD susceptibility loci
(or genetic risk factors) besides APOE, and at least one
On average, EOFAD mutations in PSEN2 exhibit a later
of these loci was predicted to exert a much greater
age of onset than those in APP or PSEN1.
effect on AD than APOE (Daw et al., 2000). In addition
The genetics of late-onset AD (LOAD) is considerably
to association studies of AD with candidate genes cho-
more difficult to address, because for this form of the sen on the basis of pathobiological arguments, com-
disease even linkage studies performed with arguably plete genome screens have been performed in attempts
reasonable sample sizes (i.e., 500–1000 families) may to find genetic linkage to novel AD loci. These studies
not be sufficiently powerful to identify genetic factors have revealed candidate AD regions on several different
of small or modest effect. Rather, these loci stand a chromosomes, most notably on chromosomes 12, 10,
better chance of detection through studies of associa- and 9 (Kehoe et al., 1999; Pericak-Vance et al., 1997).
tion or linkage disequilibrium, i.e., testing for cosegrega- Because these latter genomic regions meet the critical
tion of a particular allele(s) and disease phenotype criteria (1) of having been replicated in subsequent, inde-
across individual cases and families, ideally in regions pendent studies and (2) of being characterized by both
of established or, at least, suggestive linkage (Figure 2). positive linkage and positive association findings, they
It was this type of positional candidate gene strategy are more likely to represent authentic signals for novel
that in 1993 led to the discovery of a common variant, AD genes and merit further investigation.
4, of the gene encoding apolipoprotein E (APOE) as a Chromosome 12. In the late nineties, genetic linkage
risk factor for AD (Strittmatter et al., 1993). In contrast studies from three independent laboratories described
to all other association-based findings in AD, the associ- evidence for a putative AD locus on the short arm and
ation with APOE-4 has been consistently replicated in in the vicinity of the centromeric region of chromosome
a large number of studies across many ethnic groups 12 (St. George Hyslop, 2000; Bertram and Tanzi, 2001).
and has also been found in early-onset “sporadic” AD Two of these associated genes encode 2-macroglobu-
(for a recent meta-analysis, see Farrer et al., 1997). In lin (A2M) and its receptor, the low-density lipoprotein
addition to the increased risk exerted by the 4 allele, receptor-related protein (LRP1), both of which have
several studies have also reported a weak, albeit signifi- been shown to play roles in mediating the clearance
cant, protective effect for the least frequent allele, 2. and degradation of A (Tanzi, 1999; Figure 1). LRP also
Despite its established association, the APOE-4 al- serves as a receptor for apolipoprotein E and certain
lele is neither necessary nor sufficient to cause AD, but secreted forms of APP. The original association between
A2M was demonstrated using family-based associationinstead operates as a genetic risk modifier by decreas-
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and LRP1, and their demonstrated role in clearing cere-
bral A (Figure 1) further support the candidacy of these
genes as novel AD loci.
Chromosome 10. Recently, three laboratories reported
significant linkage of LOAD to two regions of the long
arm of chromosome 10 (Bertram et al., 2000; Ertekin-
Taner et al., 2000; Myers et al., 2000). One study followed
up “suggestive” linkage results on this chromosome us-
ing an affected sibling pair method resulting in signifi-
cant linkage near  67 Mb. Using a different methodol-
ogy, a second study (Ertekin-Taner et al., 2000)
performed multipoint linkage analyses in five late-onset
AD families using A plasma levels as a quantitative
phenotype and found significant linkage very close to
the same chromosomal region. The third report (Bertram
et al., 2000) was a candidate gene-driven linkage analy-
sis of 435 families using six genetic markers in a regionFigure 2. Strategy for Identifying Novel AD Genes
of chromosome 10 that lies 40 Mb distal to the oneCandidate genes are chosen as either “positional candidates” from
implicated by the former two studies. The candidatechromosomal regions implicated by genetic linkage studies and/or
as “biological candidates” implicated by pathobiological studies of gene of interest encodes the insulin-degrading enzyme
AD. DNA variants (e.g., SNPs) in these candidate genes are tested (IDE) that, together with neprilysin and other proteases,
for association using either case control or family-based studies. has been previously suggested to play a major role in
For those yielding positive association, independent samples are
the degradation and clearance of A in brain (see Selkoe,tested for confirmation. If confirmatory studies are consistently posi-
2001, in this issue of Neuron; Figure 1). Two of the sixtive, the variant is likely to be pathogenic. If the association cannot
markers in this region showed significant linkage to AD.be replicated, the initial results most likely represent a false positive
finding. If confirmation is inconsistent, the possibility of linkage dis- In addition, one marker, D10S583, displayed significant
equilibrium, a minor gene effect (or a false positive finding) must be association with AD through an under representation of
considered. one of its alleles in affecteds versus unaffecteds, possi-
bly indicating linkage disequilibrium with a disease mod-
ifying DNA variant nearby.methods (Blacker et al., 1998; Figure 2). However, most
Similar to the situation with A2M and LRP on chromo-subsequent independent attempts to corroborate this
some 12, a large genomic distance (40 Mb) separatesfinding in independent laboratories using mainly the
the two linked regions on chromosome 10, and presentlyclassical case control design, were negative. In fact, a
it remains unclear as to whether there are one or tworecent meta analysis concluded that “A2M is not geneti-
AD loci on this chromosome. Additional studies of link-cally associated with LOAD in white patients or mixed
age and association/linkage disequilibrium are needed
populations as found in the United States” (Koster et
to identify the putative underlying AD gene(s) (Figure
al., 2000). On the other hand, at least nine separate
2). This will also require the identification of sequence
studies have reported significant association between
variants in IDE and other candidate genes (e.g. the gene
polymorphisms in A2M and AD across various ethnic
encoding the urokinase type plasminogen activator
groups, using either case control or family-based meth- [PLAU], which has been shown to be involved in A
ods (reviewed in Bertram and Tanzi, 2001). Although the degradation) in families that are strongly linked to this
combination of numerous confirmations makes it seem region as well as those linked to the more proximal
unlikely that the initial findings were due to type I error region of chromosome 10 implicated by the two other
alone, this scenario cannot yet be excluded. However, linkage studies. Systematic linkage-disequilibrium map-
an alternative explanation is the presence of linkage ping using high-throughput SNP genotyping should ef-
disequilibrium, i.e., cosegregation of the actual (and as fectively narrow down these candidate gene regions
yet undefined) disease predisposing DNA variant and and eventually lead to the identification of potentially
the originally associated polymorphism(s) in A2M. These pathogenic DNA variants in either or both linked sections
considerations are supported by the results of a haplo- of this chromosome (Figure 2).
type-based study of A2M, showing a firm association Chromosome 9. As early as 1995, a case control study
of this locus with AD in the absence of APOE-4 (Verpillat revealed significant association with a common poly-
et al., 2000). morphism in the gene encoding the very low-density
Roughly 50 Mb proximal to A2M lie two additional lipoprotein receptor (VLDL-R), which also serves as a
candidate AD genes: LRP1 and TFCP2, the latter being receptor for apolipoprotein E containing lipoproteins,
a transcriptional factor located near LRP1. Polymor- located at the telomere of the short arm on chromosome
phisms in these genes have been associated with AD 9. As for the other proposed AD risk factors outlined
in case control studies and have been followed by both above, this report was followed by a series of both repli-
replications and refutations (reviewed in Bertram and cations and refutations. Four years later, the genome
Tanzi, 2001). Collectively, the presence of significant scan by Kehoe et al. (1999) reported “suggestive” evi-
linkage and association in both chromosomal regions dence of linkage in two regions on chromosome 9: one
may indicate the existence of two distinct AD genes on 25 Mb and the other100 Mb away from the telomere
chromosome 12, one being A2M (or a gene nearby) and of the short arm of this chromosome and VLDL-R. More
the other being LRP1 (or a gene nearby, e.g., TFCP2). recently, significant linkage was reported in autopsy
confirmed AD cases using an overlapping set of familiesThe known interaction of the proteins encoded by A2M
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for the more proximal locus (Pericak-Vance et al., 2000). most importantly, (4) replicating positive findings in inde-
Again, the situation on chromosome 9 is reminiscent of pendent datasets.
that which has evolved on chromosomes 10 and 12: two Fortunately, access to sufficiently large family sam-
separate linkage signals in two distinct regions of the ples will allow the simultaneous evaluation of linkage
same chromosome, which may indicate the presence and association, without being subject to the possible
of two separate AD genes, but may also be caused by drawbacks of the more classical case control design.
the same locus. At this point, it remains unclear whether Furthermore, the development of increasingly powerful
or not VLDL-R is responsible for the linkage observed and sophisticated genotyping and analytic methodolo-
on the short arm of chromosome 9. However, the gies will greatly facilitate the large-scale identification
strength of the linkage signal(s) observed in two differ- of novel AD genes. This knowledge will eventually en-
ent—although not entirely independent—studies clearly gender reliable genetic risk profiling protocols for the
warrant the evaluation of additional candidate genes early prediction of AD, and foster the development of
and markers on this chromosome. effective therapeutic strategies for the early prevention
Conclusion and treatment of this devastating disorder.
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